BibTex format

author = {Singh, D and Agusti, A and Anzueto, A and Barnes, PJ and Bourbeau, J and Celli, BR and Criner, GJ and Frith, P and Halpin, DMG and Han, M and López, Varela MV and Martinez, F and Montes, de Oca M and Papi, A and Pavord, ID and Roche, N and Sin, DD and Stockley, R and Vestbo, J and Wedzicha, JA and Vogelmeier, C},
doi = {10.1183/13993003.00164-2019},
journal = {European Respiratory Journal},
title = {Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD Science Committee Report 2019},
url = {},
volume = {53},
year = {2019}

RIS format (EndNote, RefMan)

AB - Precision medicine is a patient specific approach that integrates all relevant clinical, genetic and biological information in order to optimise the therapeutic benefit relative to the possibility of side effects for each individual. Recent clinical trials have shown that higher blood eosinophil counts are associated with a greater efficacy of inhaled corticosteroids (ICS) in COPD patients. Blood eosinophil counts are a biomarker with potential to be used in clinical practice, to help target ICS treatment with more precision in COPD patients with a history of exacerbations despite appropriate bronchodilator treatment.The Global initiative for the management of chronic Obstructive Lung Disease (GOLD) 2017 pharmacological treatment algorithms, based on the ABCD assessment, can be applied relatively easily to treatment naïve individuals at initial presentation. However, their use is more problematic during follow up in patients who are already on maintenance treatment. There is a need for a different system to guide COPD pharmacological management during follow up.Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICS and long-acting bronchodilators on exacerbations. The new evidence regarding blood eosinophils and inhaled treatments, and the need to distinguish between initial and follow up pharmacological management, led to changes in the GOLD pharmacological treatment recommendations. This paper explains the evidence and rationale for the GOLD 2019 pharmacological treatment recommendations.
AU - Singh,D
AU - Agusti,A
AU - Anzueto,A
AU - Barnes,PJ
AU - Bourbeau,J
AU - Celli,BR
AU - Criner,GJ
AU - Frith,P
AU - Halpin,DMG
AU - Han,M
AU - López,Varela MV
AU - Martinez,F
AU - Montes,de Oca M
AU - Papi,A
AU - Pavord,ID
AU - Roche,N
AU - Sin,DD
AU - Stockley,R
AU - Vestbo,J
AU - Wedzicha,JA
AU - Vogelmeier,C
DO - 10.1183/13993003.00164-2019
PY - 2019///
SN - 0903-1936
TI - Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD Science Committee Report 2019
T2 - European Respiratory Journal
UR -
UR -
UR -
VL - 53
ER -